AMAG Pharmaceuticals, Inc. (AMAG) Stake Lessened by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. decreased its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 4.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 290,795 shares of the specialty pharmaceutical company’s stock after selling 11,973 shares during the period. Schwab Charles Investment Management Inc. owned about 0.83% of AMAG Pharmaceuticals worth $5,351,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Sei Investments Co. grew its holdings in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after purchasing an additional 54 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of AMAG Pharmaceuticals by 1.7% in the first quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company’s stock worth $404,000 after purchasing an additional 300 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of AMAG Pharmaceuticals by 2.1% in the second quarter. Louisiana State Employees Retirement System now owns 14,300 shares of the specialty pharmaceutical company’s stock worth $263,000 after purchasing an additional 300 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its holdings in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock worth $152,000 after purchasing an additional 510 shares during the last quarter. Finally, Mason Street Advisors LLC grew its holdings in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after purchasing an additional 554 shares during the last quarter.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 17.50 on Friday. The stock’s market cap is $617.54 million. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83. The company has a 50-day moving average price of $18.49 and a 200-day moving average price of $19.31.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. AMAG Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 EPS. Equities analysts anticipate that AMAG Pharmaceuticals, Inc. will post ($1.38) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://sportsperspectives.com/2017/10/13/amag-pharmaceuticals-inc-amag-stake-lessened-by-schwab-charles-investment-management-inc.html.

AMAG has been the topic of several recent analyst reports. Cantor Fitzgerald restated a “hold” rating and issued a $21.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Cowen and Company restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a report on Wednesday, October 4th. Morgan Stanley initiated coverage on shares of AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price on the stock. Finally, BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $27.67.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply